Events

Investival Showcase Virtual w/ Jackie Hunter

External And Internal Convergence - A Cross-Sector Approach To Healthcare’s Biggest Challenges.

Wednesday, November 11 - 14:45 GMT

As health economies face challenges of improving outcomes while lowering cost, among many others, a cross-sector approach to health and care is vital. Alongside new biotechnologies and combination therapeutic approaches has come the rapid expansion of AI in multiple settings, new digital technologies and, importantly, the more tech-savvy and engaged patient, convergence is starting to make meaningful impacts. How is the industry developing new core digital capabilities, alliances, partnerships and innovative ways to drive better outcomes? 

  • In which ways are health and care industry leaders’ driving solutions to healthcare’s biggest challenges through different therapeutics, digital, and device combination approaches? 
  • To what extent and in which ways does external innovation fit into this picture for pharma companies like J&J? 
  • How can the wider industry work towards true and meaningful convergence to improve outcomes? 
  • How can this holistic approach and personalised medicine approaches go hand in hand? 

Panelists:

Melanie Senior, Writer and Analyst (moderator) 

Prabhu Velusami, Senior Director, New Ventures and Transactions, Johnson & Johnson 

Dan Vahdat, CEO, Huma 

Nikolaj Sorensen, CEO, Orexo 

Jackie Hunter, Board Director, BenevolentAI 

Eric Marcotulli, CEO, Elysium Health

Register →


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020